Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Market Closed - Nasdaq Stockholm
Other stock markets
 06:59:42 2024-04-30 EDT 		5-day change 1st Jan Change
110 SEK +2.90% Intraday chart for Calliditas Therapeutics AB +9.67% -13.45%
04-25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
04-24 Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Calliditas Therapeutics' 2023 Annual Report Published
AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results
AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
AQ
Calliditas Therapeutics to Attend Conferences in April
AQ
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
AQ
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
AQ
Calliditas Therapeutics : February 21, 2024 Year-end report 2023 (Presentation)
PU
Calliditas announces an additional seven year orphan drug exclusivity Period for TARPEYO
AQ
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®
AQ
Calliditas Therapeutics to Attend Investor Conferences in March
AQ
Calliditas Therapeutics to Attend Investor Conferences in March
AQ
Calliditas Year-end report, January - December 2023
AQ
Invitation to the presentation of Calliditas' Year-end report January - December 2023
AQ
Calliditas provides patent update
AQ
Calliditas Therapeutics appoints Maria Tornsen as President North America
AQ
Calliditas Therapeutics provides business update ahead of JP Morgan conference
AQ
Calliditas Therapeutics appoints Maria Törnsén as President North America
AQ
Calliditas to present at JP Morgan Healthcare Conference
AQ
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital
AQ
Everest Medicines Partner Calliditas Therapeutics Announces Nefecon the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. News Calliditas Therapeutics AB
  5. Press Releases